Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Chevallier

Showing results (271-280 of 294) with videos related to

Pageof 30
Sort By:
Bone Marrow Transplantation|March 29, 2011
Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantationZ Peric, X Cahu, P Chevallier, et al.
Leukemia|February 19, 2011
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS studyP Chevallier, M Labopin, P Turlure, et al.
Leukemia|May 29, 2010
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trialP Chevallier, L Fornecker, B Lioure, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|February 26, 2011
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantationZ Peric, X Cahu, P Chevallier, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Journal of AOAC International|January 13, 2021
Food Fingerprinting: Using a Two-Tiered approach to Monitor and Mitigate Food Fraud in RiceTerence F McGrath, Maeve Shannon, Olivier P Chevallier, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Bone Marrow Transplantation|September 15, 2015
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?R Peffault de Latour, M Labopin, J Cornelissen, et al.
Pageof 30

Showing results (271-280 of 294) with videos related to

Sort By:
Pageof 30
Bone Marrow Transplantation|March 29, 2011
Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantationZ Peric, X Cahu, P Chevallier, et al.
Leukemia|February 19, 2011
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS studyP Chevallier, M Labopin, P Turlure, et al.
Leukemia|May 29, 2010
Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trialP Chevallier, L Fornecker, B Lioure, et al.
Bone Marrow Transplantation|June 2, 2015
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMTJ R Passweg, M Labopin, J Cornelissen, et al.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|February 26, 2011
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantationZ Peric, X Cahu, P Chevallier, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Journal of AOAC International|January 13, 2021
Food Fingerprinting: Using a Two-Tiered approach to Monitor and Mitigate Food Fraud in RiceTerence F McGrath, Maeve Shannon, Olivier P Chevallier, et al.
Leukemia|January 17, 2013
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapseS Park, N Chapuis, F Saint Marcoux, et al.
Bone Marrow Transplantation|September 15, 2015
In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?R Peffault de Latour, M Labopin, J Cornelissen, et al.
Pageof 30